Novo Nordisk

Novo Nordisk invested 3.5 billion Czech koruna (US$168 million) in modernisation works following its US$200 million acquisition of the facility.

Under the new agreement, EDE and Novo Nordisk will work together to enhance pharmaceutical supply chain security by increasing in-country value creation and expanding strategic partnerships that help maintain a steady supply of medicines.

Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management.

Wegovy® 7.2 mg is already available in the European Union for adults with obesity through three separate 2.4 mg injections administered weekly.

Once fully operational, the hub is expected to enable access to treatment for more than 2.6 million patients across a population of more than 1 billion people.

The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.

The study showed that oral semaglutide achieved a significantly greater reduction in HbA1c levels, a key marker of blood sugar control, compared to placebo.

The collaboration will enhance the company’s ability to analyze complex datasets, identify promising drug candidates, and significantly reduce the time required to bring medications to patients.